ClinicalTrialsFinder
RecruitingPhase 1NCT07471932

A Study of LAD106 in Healthy Adult Participants

A Phase 1, Randomized, Two-part, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacodynamics of LAD106 in Healthy Adult Participants

Sponsor

Almirall, S.A.

Enrollment

93 participants

Start Date

Feb 17, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Volunteers

Summary

The main aim of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of single ascending doses of LAD106 (Part A) and multiple ascending doses of LAD106 (Part B) in human healthy participants.

Eligibility

Min Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called LAD106, a drug called Lebrikizumab, and others for people with healthy volunteers. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLAD106

LAD106 will be administered.

DRUGLebrikizumab

Lebrikizumab will be administered.

OTHERPlacebo

Placebo matching LAD106 will be administered.

Locations(1)

Centre for Human Drug Research (CHDR) Phase 1 Unit

Leiden, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07471932

Related Trials

Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection

NCT077066861 location

A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants

NCT076731201 location

Mechanism of Non-invasive Magnetic Stimulation

NCT033940661 location

Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants

NCT076299991 location

Sociocultural & Biobehavioral Influences on Pain Expression and Assessment

NCT032585801 location